Leah Lawrence

An increased rate of adverse effects is seen in patients with differentiated thyroid cancer who are being treated with the tyrosine kinase inhibitor sorafenib.

Treatment with the BCR-ABL tyrosine kinase inhibitors dasatinib, nilotinib, and ponatinib was associated with increased risk for vascular occlusive events in patients with CML compared with imatinib.

The use of a standard yearly physical examination to screen for thyroid cancer among high-risk survivors of childhood and young adult cancers resulted in a negative predictive value of 100% for clinically relevant thyroid cancer and a significant cost savings compared with regular ultrasound screening.

A median overall survival of longer than 2 years was achieved in a group of patients with metastatic melanoma assigned to treatment with the combination of dabrafenib and trametinib.

Older patients with AML who are ineligible for intensive chemotherapy achieved improved overall survival when assigned to low-dose gemtuzumab ozogamicin.

The FDA granted approval to ofatumumab for the treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial remission after two or more lines of prior therapy.

A combination of four biomarkers may be able to help clinicians identify patients who have a high-risk type of colorectal cancer.

Pancreatic cancer patients who received adjuvant therapy at a high-volume center had superior overall survival vs patients who were treated in a community setting.

The FDA recently expanded the drug label for carfilzomib (Kyprolis), which is now approved in combination with dexamethasone or with lenalidomide plus dexamethasone for patients with relapsed or refractory disease who have received one to three lines of therapy.

Survivors of thyroid cancer are at an increased risk for developing a second cancer, according to the results of a recently published study.

A short-course of preoperative radiation therapy plus consolidated chemotherapy was shown to be as effective as standard preoperative chemoradiation in the treatment of locally advanced rectal cancer.

Regular ultrasound surveillance of the thyroid revealed that about 7% of adult childhood cancer survivors who had radiation to the head or neck subsequently developed thyroid cancer.

Long-term study results show that a wider surgical margin for cutaneous melanomas greater than 2-mm thick improved melanoma-specific survival vs a 1-cm margin.

A novel drug, 177Lutetium-DOTATATE (Lutathera), significantly lowered the risk for disease progression or death among patients with previously treated, advanced midgut neuroendocrine tumors.

The use of a reduced preparation CT colonography increased participation in colonography as a method of population screening for colorectal cancer, according to the results of a large Italian study.

A new study has shown that dinaciclib disrupted homologous recombination function and led to cell death in multiple myeloma cell lines when combined with the PARP1/2 inhibitor ABT-888.

A substudy of the SOFT trial found that a number of patients assigned to adjuvant treatment with the aromatase inhibitor exemestane plus triptorelin do not achieve complete reductions in their estrogen levels.

The FDA recently expanded its approval of pembrolizumab (Keytruda) to include the initial treatment of patients with unresectable or metastatic melanoma.

Researchers have identified several factors that may help to predict the progression of vertebral fractures and future fractures in patients with multiple myeloma.

A new study has confirmed the safety and efficacy of pazopanib in a real-world setting of patients with metastatic renal cell carcinoma (mRCC) and validates the International Metastatic Renal Cell Carcinoma Database (IMDC) prognostic model in this patient population.

More than half of hematologists providing care to patients with hematologic malignancies reported initiating end-of-life conversations too late in the course of the patient’s disease.

Administering pharmacological prophylaxis against venous thromboembolism (VTE) did not decrease the occurrence of VTE in patients treated with robotic partial nephrectomy, and it did not increase the rate of hemorrhagic events.

The success of allogeneic HCT in patients with AML varied among those with complete remission and minimal residual disease positivity vs negativity.

Women with early-stage breast cancer treated with breast-conserving therapy had significantly improved 10-year overall survival compared with women who underwent mastectomy without radiation therapy.

A preclinical study looking at ER-positive breast cancer indicated that tamoxifen response was improved by reducing levels of the enzyme APOBEC3B and worsened by increasing levels of the enzyme.

Women with advanced endocrine-resistant breast cancer who had PIK3CA mutations in their circulating tumor DNA had an almost 4-month progression-free survival improvement when adding the PIK3CA inhibitor buparlisib to fulvestrant.

The addition of carboplatin to a neoadjuvant chemotherapy regimen resulted in improvements in disease-free survival for women with triple-negative breast cancer.

Patients with breast cancer who still had residual disease after undergoing neoadjuvant chemotherapy and surgery had improved survival outcomes with the addition of adjuvant capecitabine to standard treatment.

Premenopausal women with luminal A breast tumors received no benefit from treatment with adjuvant chemotherapy.

Single-agent ibrutinib resulted in significantly improved outcomes for older patients with chronic lymphocytic leukemia, compared with chlorambucil treatment.